World-Renowned Rheumatologist Researcher Brings New Scleroderma Program to Cedars-Sinai in Los Angeles

Jun 22, 2020 | Autoimmune Disease, Leading Sites, News, Scleroderma, Site Success, Site Watch

World-Renowned Rheumatologist Researcher Brings New Scleroderma Program to Cedars-Sinai in Los Angeles

Francesco Boin, MD, a nationally recognized rheumatology expert, has been appointed the director  of the division of Rheumatology and director of the new Scleroderma Program at Cedars-Sinai. An accomplished and widely published investigator of autoimmune diseases, Dr. Boin brings a renowned reputation and a multidisciplinary approach to patient care.

World Renowned Research Arrives Cedars-Sinai

A world renowned autoimmune disease researcher will bring his expertise, contacts and capabilities to Los Angeles-based Cedars Sinai reports the chair of the department of Medicine, Paul W. Nobel, MD.  Dr. Nobel commented, “The best we can offer our patients is tied to cutting-edge research. Dr. Boin is uniquely qualified to develop both a top translational science and clinical research center as well as a treatment and consultation program for people with rheumatological diseases.”

Established UCSF Scleroderma Center

Dr. Boin established the UCSF Scleroderma Center, and served as its director, at University of California San Francisco.  Before his efforts in Northern  California, he was the director of the Translational Research program at the Johns Hopkins Scleroderma Center. Originally from Italy, he earned his medical degree cum laude from the University of Padua School of Medicine.

What is Scleroderma?

An autoimmune disease causing an overproduction of collagen, symptoms can range from changes in the skin or muscle to hardening of life-sustaining organs. An estimated 300,000 people in the U.S. have been diagnosed with the illness. Dr. Boin commented, “It is the epitome of complex autoimmune rheumatoid disorders because it can affect any organ in the body. Scleroderma is a chronic illness that can replace an incredible burden on patients and their families over a long period of time.”

The New Kao Autoimmunity Institute

Now the new Scleroderma Program at Cedars-Sinai will be part of the new Kao Autoimmunity Institute, whose mission is to advance treatment and research of rheumatologic diseases. The institute was created last fall with a $20 million gift from Dr. and Mrs. Min H. Kao and the Kao Family Foundation.

And with Dr. Boin on board, the principal investigator and key opinion leaders will center attention on the causes of this diseases, including mechanisms that trigger its development.

Lead Research/Investigator

Francesco Boin, MD 

Call to Action: Does you or a loved one have an autoimmune disease such as Scleroderma and reside in Southern California? If so, consider contacting Cedars-Sinai and the new Kao Autoimmunity Institute.

Source: Cedars-Sinai


Pin It on Pinterest